VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LIVN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LIVNLivaNova PLC
$91.92$5.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLIVNFinancials

LivaNova PLC (LIVN) Income Statement

30Y historyFree accessUpdated daily

Revenue grew from $318.6M to $393.1M over the ten quarters while operating margin fell from 15.4% in 2025Q2 to 7.2% in 2026Q3, suggesting rising operating costs are eroding the stable 67.4% gross margin.

Income StatementBalance SheetCash FlowRatios

LIVN Income Statement

Annual statement

LIVN Income Statement

LivaNova PLC (LIVN) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Apr'15Apr'14Apr'13Apr'12Apr'11Apr'10Apr'09Apr'08Apr'07Apr'06Apr'05Apr'04Apr'03Apr'02Jun'00Jun'99Jun'98Jun'97Jun'96Jun'95
Sales/Revenue1.51B1.39B1.25B1.15B1.02B1.04B934.24M1.08B1.11B1.01B1.21B291.56M282.01M254.32M218.5M190.46M167.78M143.6M121.23M130.97M123.44M103.44M110.72M104.47M70.11M47.89M29.9M14.9M1.4M1.4M1M
Revenue Growth %11.7%10.74%8.66%12.89%-1.31%10.82%-13.83%-2.06%9.35%-16.61%316.35%3.38%10.89%16.39%14.72%13.52%16.83%18.45%-7.44%6.1%19.33%-6.57%5.99%49%46.4%60.16%100.67%964.29%0%40%150%
Cost of Goods Sold483.49M448.2M382.56M382.3M314.58M329.37M339.48M360.37M372.5M360.7M509.5M27.31M27.35M21.91M19.66M23.02M20.91M20.04M21.09M18.26M15.82M15.58M16.3M16.07M13.62M10.38M6.2M3.2M100K200K0
COGS % of Revenue-32.29%30.52%33.14%30.79%31.81%36.34%33.24%33.65%35.63%41.97%9.37%9.7%8.61%9%12.09%12.46%13.96%17.4%13.94%12.82%15.06%14.72%15.38%19.42%21.68%20.74%21.48%7.14%14.29%-
Gross Profit1.02B939.9M870.87M771.25M707.23M705.99M594.76M723.8M734.5M651.6M704.4M264.25M254.66M232.41M198.85M167.44M146.87M123.56M100.14M112.71M107.62M87.87M94.43M88.4M56.49M37.5M23.7M11.7M1.3M1.2M1M
Gross Margin %67.91%67.71%69.48%66.86%69.21%68.19%63.66%66.76%66.35%64.37%58.03%90.63%90.3%91.39%91%87.91%87.54%86.04%82.6%86.06%87.18%84.94%85.28%84.62%80.58%78.32%79.26%78.52%92.86%85.71%100%
Gross Profit Growth %-7.93%12.92%9.05%0.17%18.7%-17.83%-1.46%12.72%-7.5%166.57%3.77%9.57%16.88%18.75%14.01%18.86%23.39%-11.15%4.73%22.48%-6.95%6.82%56.48%50.63%58.25%102.56%800%8.33%20%66.67%
Operating Expenses850.62M740.5M741.82M839.75M783.98M706.78M868.66M895.36M648.2M523.4M637.2M166.9M167.2M154.07M137.9M118.26M110.01M104.57M108.37M162.24M166.85M100.77M87.73M83.72M83.71M42.76M37.8M27.9M12.7M11.6M8.9M
OpEx % of Revenue-53.35%59.18%72.8%76.72%68.26%92.98%82.58%58.55%51.7%52.49%57.25%59.29%60.58%63.11%62.09%65.57%72.82%89.39%123.87%135.17%97.42%79.24%80.14%119.39%89.28%126.42%187.25%907.14%828.57%890%
Selling, General & Admin599.93M548.8M526.26M518.13M469.24M471.9M00465M380.6M469.2M123.62M120.64M112.52M102.57M89.65M87.94M84.84M85.94M134.14M137.31M81.43M70.6M65.84M59.19M33.27M29.6M19.8M5.9M3.4M8.6M
SG&A % of Revenue-39.54%41.99%44.92%45.92%45.58%--42.01%37.6%38.65%42.4%42.78%44.24%46.94%47.07%52.42%59.08%70.89%102.42%111.23%78.72%63.76%63.03%84.42%69.47%99%132.89%421.43%242.86%860%
Research & Development202.57M185.8M182.51M193.82M155.81M183.41M152.9M197.15M146M109.7M122.5M43.28M46.56M41.55M35.33M28.6M22.06M19.73M22.42M28.09M29.54M19.34M17.13M17.87M24.52M8.04M6.7M7.4M6.5M8M0
R&D % of Revenue-13.39%14.56%16.8%15.25%17.71%16.37%18.18%13.19%10.84%10.09%14.85%16.51%16.34%16.17%15.02%13.15%13.74%18.49%21.45%23.93%18.7%15.47%17.11%34.97%16.78%22.41%49.66%464.29%571.43%-
Other Operating Expenses3M5.9M33.04M127.8M158.93M51.46M715.76M698.21M37.19M33.14M45.51M642.36K-295.27K000000000006001.45M1.5M700K300K200K300K
Operating Income172.7M199.4M129.05M-68.5M-76.75M-784K-273.9M-171.55M-248.1M95.7M-27.6M88.65M80.01M78.35M60.94M49.19M36.86M18.99M-8.23M-49.53M-59.23M-12.91M6.7M4.68M-27.21M-5.25M-14.1M-16.2M-11.4M-10.4M-7.9M
Operating Margin %11.46%14.37%10.3%-5.94%-7.51%-0.08%-29.32%-15.82%-22.41%9.45%-2.27%30.41%28.37%30.81%27.89%25.83%21.97%13.22%-6.79%-37.82%-47.98%-12.48%6.05%4.48%-38.81%-10.97%-47.16%-108.72%-814.29%-742.86%-790%
Operating Income Growth %-54.51%288.4%10.75%-9689.8%99.71%-59.66%30.85%-359.25%446.74%-131.13%10.8%2.13%28.56%23.9%33.44%94.12%330.77%83.39%16.39%-358.98%-292.76%42.95%117.21%-418.23%62.76%12.96%-42.11%-9.62%-31.65%-21.54%
EBITDA247.6M241.4M180.19M-7.64M-18.96M67.2M-192.58M-88.56M-178.16M165.9M57.76M95.91M85.61M82.98M65.67M51.93M39.09M21.17M-4.27M-45.04M-54.74M-8.92M11.61M9.8M-22.92M-3.8M-12.6M-15.5M-11.1M-10.2M-7.6M
EBITDA Margin %16.43%17.39%14.38%-0.66%-1.86%6.49%-20.61%-8.17%-16.09%16.39%4.76%32.89%30.36%32.63%30.06%27.26%23.3%14.74%-3.52%-34.39%-44.35%-8.62%10.49%9.38%-32.69%-7.94%-42.14%-104.03%-792.86%-728.57%-760%
EBITDA Growth %-1.48%33.97%2457.96%59.69%-128.21%134.9%-117.44%50.29%-207.39%187.2%-39.77%12.02%3.17%26.36%26.47%32.83%84.65%595.85%90.52%17.73%-513.83%-176.8%18.45%142.77%-502.93%69.83%18.71%-39.64%-8.82%-34.21%-22.58%
D&A (Non-Cash Add-back)48.5M42M51.14M60.86M57.8M67.99M81.32M82.99M69.94M70.2M85.36M7.25M5.6M4.64M4.73M2.74M2.23M2.18M3.96M4.49M4.49M3.99M4.92M5.12M4.29M1.45M1.5M700K300K200K300K
EBIT162.87M-171.5M151.38M-22.37M-26.89M-74.32M-60.99M48.49M-237.62M128.94M35.82M-56.66M89.31M79.9M75.39M60.72M49.06M39.92M30.84M-8.23M-49.53M-59.23M-19.3M4.55M4.68M-5.25M-5.25M-14.1M-16.2M-11.4M-10.4M
Net Interest Income-33.28M-30.3M-32.99M-36.84M-43.55M-49.72M-40.71M-14.29M-8.98M-6.48M-8.92M0163K162K-35K29.39K-135.68K-1.34M-2.16M-1.97M-1.26M192.99K628.22K-95.78K998.58K000000
Interest Income9.99M18.98M30.07M22.01M4.7M435K131K803K847K1.32M1.7M0182.27K182K84K326.12K92.6K1.24M3.84M4.65M3.21M1.07M469.92K469.92K1.26M000000
Interest Expense43.28M49.29M63.07M58.85M48.25M50.15M40.84M15.09M9.82M7.8M10.62M162.89K20.05K20K119K296.73K1.43M3.39M5.82M5.91M3.02M444.27K565.7K565.7K266.27K44.89K00000
Other Income/Expense-53.12M-420.2M-40.74M-12.83M1.56M-123.84M-74.39M43.92M625K24.65M-66.45M-130.98M642K-133K-3.07M-521.42K-522.71K1.63M8.46M-2.37M-1.57M262.45K712.95K-1.85M93.69K-44.89K5.25M2M5M1.3M3.2M
Pretax Income119.59M-220.8M88.31M-81.33M-75.19M-124.62M-348.29M-127.63M-247.4M121.1M-33M89.29M79.88M75.27M60.42M48.66M38.49M27.45M-10.6M-51.1M-58.97M-12.19M6.99M5.31M-27.12M-5.3M-14M-14.2M-11.2M-10.1M-7.2M
Pretax Margin %7.94%-15.91%7.05%-7.05%-7.36%-12.04%-37.28%-11.77%-22.35%11.96%-2.72%30.63%28.32%29.6%27.65%25.55%22.94%19.12%-8.74%-39.02%-47.77%-11.79%6.31%5.09%-38.68%-11.06%-46.82%-95.3%-800%-721.43%-720%
Income Tax-76.67M21.6M25.06M-98.88M11.05M11.2M-960K-30.37M-69.63M49.95M5.11M31.45M31.45M24.99M28.92M24.34M1.94M-39.96M729.44K-264.84K78.78K99.27K26.11K230.79K129.56K-2.15M00000
Effective Tax Rate %-64.11%-9.78%28.38%121.57%-14.7%-8.99%0.28%23.8%28.14%41.25%-15.49%35.22%39.37%33.2%47.86%50.02%5.04%-145.57%-6.88%0.52%-0.13%-0.81%0.37%4.34%-0.48%40.65%0%0%0%0%0%
Net Income196.08M-242.5M63.23M17.55M-86.25M-135.82M-348.82M-157.64M-189.4M-25.1M-62.8M57.85M54.89M46.36M36.08M46.73M78.45M26.72M-10.33M-51.18M-59.07M-12.22M6.76M5.18M-26.12M-3.05M-12.5M-14.2M-11.2M-10.1M-7.2M
Net Margin %13.01%-17.47%5.04%1.52%-8.44%-13.12%-37.34%-14.54%-17.11%-2.48%-5.17%19.84%19.46%18.23%16.51%24.53%46.76%18.61%-8.52%-39.08%-47.85%-11.81%6.11%4.96%-37.25%-6.38%-41.81%-95.3%-800%-721.43%-720%
Net Income Growth %190.16%-483.5%260.39%120.34%36.5%61.06%-121.28%16.77%-654.58%60.03%-208.56%5.39%18.41%28.49%-22.79%-40.44%193.59%358.55%79.81%13.36%-383.45%-280.76%30.37%119.85%-755.48%75.57%11.97%-26.79%-10.89%-40.28%-22.03%
Net Income (Continuing)196.16M-242.5M63.25M17.55M-86.25M-135.82M-347.33M-158M-177.82M71.18M20.55M-22.08M57.85M54.89M46.36M36.08M46.73M78.45M26.72M-10.33M-51.18M-59.07M-18.61M4.62M5.18M-3.05M-3.93M-12.5M-14.2M-11.2M-10.1M
Discontinued Operations000000-1.49M365K0-79.55M-64.66M-22.34M0000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)3.42-4.451.160.32-1.61-2.68-7.06-3.22-3.91-0.52-1.282.172.001.661.271.632.730.97-0.39-2.01-2.37-0.510.260.24-1.21-0.17-0.71-0.88-0.93-1.06-0.79
EPS Growth %187.5%-483.62%262.5%119.88%39.93%62.04%-119.25%17.65%-651.92%59.38%-158.99%8.5%20.48%30.71%-22.09%-40.29%181.44%348.72%80.6%15.19%-364.71%-296.15%8.33%119.83%-611.76%76.06%19.32%5.38%12.26%-34.18%-19.7%
EPS (Basic)--4.451.170.33-1.61-2.68-7.06-3.22-3.91-0.52-1.292.192.021.681.301.672.831.00-0.39-2.01-2.37-0.510.290.24-1.21-0.17-0.71-0.88-0.93-1.06-0.79
Diluted Shares Outstanding57.4M54.5M54.57M54.21M53.5M50.63M48.59M48.35M48.5M48.5M48.9M26.63M27.47M28.01M28.31M28.61M28.7M27.54M26.5M25.51M24.92M24.04M25.66M22.03M21.66M18.04M17.5M16.1M12.04M9.51M9.11M
Basic Shares Outstanding55.1M54.5M54.24M53.9M53.5M50.63M48.59M48.35M48.5M48.2M48.86M26.39M27.14M27.6M27.83M28.05M27.7M26.63M26.5M25.51M24.92M24.04M23.09M22.03M21.66M18.04M17.5M16.1M12.04M9.51M9.11M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeStable
ProfitabilityStrained
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Non-operating charges eroding earnings

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Mid-Single-Digit Revenue Growth Persisting

Based on LivaNova's reported quarterly figures, revenue rose from $318.6M in 2024Q2 to $393.1M in 2026Q3, with year-over-year growth running between roughly 5% and 11% across recent quarters, suggesting steady rather than accelerating expansion.

The most recent quarters show growth in the 9.9% to 10.8% range, a modest improvement from the single-digit prints seen in 2024 and early 2025, which may indicate Cardiopulmonary and Neuromodulation demand is firming. Investors should monitor whether this pace is sustained without reliance on the Q1 2025 distortion, since the reported revenue series does not disclose volume versus pricing contributions needed to judge durability.

Gross Margin Holding Near Two-Thirds

Reported gross margins have oscillated between 66.4% and 70.8% over the ten-quarter window, with the latest 2026Q3 print at 67.4%, which points to a stable premium pricing structure in implantable and disposable products.

The consistency of gross margin across quarters suggests limited erosion from input cost or pricing pressure, consistent with specialized implantable technology commanding durable pricing. Because the data does not separate segment-level margins, it is unclear how much of the blended figure is carried by high-margin VNS implants versus lower-margin capital equipment, which warrants further investigation.

Operating Margin Compressing Despite Revenue Gains

Operating margin declined from 15.4% in 2025Q2 to 7.2% in 2026Q3 even as revenue grew, based on reported figures, indicating operating costs are expanding faster than the gross profit base.

SG&A rose from about $133.7M in 2025Q1 to $154.9M in 2026Q3, absorbing much of the gross profit gains and implying negative operating leverage over the period. This pattern may reflect commercial investment or cost inflation, but without disclosure on the drivers of SG&A growth, investors should treat the deterioration as a signal to monitor rather than a settled conclusion.

Net Income Diverging From Operating Results

Reported net income swings sharply, including a $327.3M loss in 2025Q1 and a $108.6M gain in 2026Q2, while operating income remained comparatively steady, suggesting large non-operating items are driving bottom-line volatility.

The gap between operating income and net income implies substantial non-operating charges or gains that are not explained in the supplied data, and these appear to dominate reported EPS. Stock-based compensation of $7.8M to $16.9M per quarter is modest relative to these swings, so it does not appear to be the primary explanation, leaving the reconciliation between GAAP and operating earnings as a key diligence item.

Recurring Charges May Mask Core Weakness

The steady erosion from a 15.4% operating margin in 2025Q2 to 7.2% in 2026Q3, combined with a reported trailing net margin of -17.5%, may indicate that headline earnings beats overstate the underlying profitability trend.

A bear case would argue that recurring restructuring-type costs and legacy litigation drag are being treated as non-recurring, which could make adjusted metrics look better than the reported economics. The strongest challenge is that the Q3 2026 EPS beat is not matched by a sustained margin recovery, so forward estimates built on the beat may prove optimistic if SG&A growth continues to outpace gross profit.

LIVN — Frequently Asked Questions

Quick answers to the most common questions about buying LIVN stock.

What was LivaNova PLC's (LIVN) revenue in 2025?

For fiscal year 2025, LivaNova PLC (LIVN) reported total revenue of $1.39B. This represents a 138710.0% increase compared to $1.0M in 1995.

Is LivaNova PLC (LIVN) profitable?

LivaNova PLC (LIVN) reported a net loss of $242.5M for the fiscal year ending 2025.

What is LivaNova PLC's operating profit margin?

LivaNova PLC (LIVN) reported an operating income of $199.4M, resulting in an operating profit margin of 14.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is LivaNova PLC's gross profit and gross margin?

LivaNova PLC (LIVN) generated $939.9M in gross profit for the year, representing a gross profit margin of 67.7%. This demonstrates the company's core pricing power and production efficiency.